Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B

This study has suspended participant recruitment.
(Study currently suspended due to a lack of available funding.)
Sponsor:
Information provided by:
Nanogen, Inc.
ClinicalTrials.gov Identifier:
NCT00828100
First received: January 20, 2009
Last updated: March 5, 2009
Last verified: March 2009

January 20, 2009
March 5, 2009
February 2009
May 2009   (final data collection date for primary outcome measure)
Positive percent agreement and negative percent agreement for both influenza A and influenza B. [ Time Frame: End of study ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00828100 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B
Comparison of fluID Rapid Influenza and BinaxNOW® Influenza A & B

The primary objective of this study is to compare the performance of the investigational fluid Rapid Influenza Test and the BinaxNOW® Influenza A & B Test in detecting influenza type A and influenza type B.

The primary objective of this study is to compare the performance of the investigational fluID Rapid Influenza Test and the BinaxNOW® Influenza A & B Test in detecting influenza type A and influenza type B, with respect to fresh nasal wash / aspirate specimens collected from patients presenting with signs and symptoms of influenza-like illness (ILI). Specimens to be evaluated in this study will be enrolled in a concurrent clinical study per protocol FLU-05, entitled "Prospective Evaluation of the fluID Rapid Influenza Test". All subjects enrolled in the FLU-05 study will have consented to having their samples used in future investigations involving the fluID Test.

This study will be conducted during the 2008-2009 influenza season in North America and Hong Kong, which is anticipated to run from November 2008 to May 2009. Should the influenza season conclude in North America and Hong Kong prior to the attainment of the minimum target enrollment specified in the FLU-05 study, study sites in Australia will also be enlisted in order to enroll subjects; in such a case, enrollment will continue during the 2009 influenza season in these countries, which is anticipated to run from May through October, 2009.

Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Influenza
  • Device: fluID Rapid Influenza Test
    The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC) setting.
  • Device: BinaxNOW® Influenza A & B
    The BinaxNOW Influenza A & B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
650
Not Provided
May 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female subjects of any age;
  2. Subjects presenting to the investigative site within 4 days of symptom onset, with:

    • Fever ≥ 38.0°C (100.4°F) if taken orally, or ≥ 38.5°C (101.2°F) if taken rectally; or a self-reported history of fever or feeling feverish (includes fever controlled by medication) in the absence of documented fever;
    • One or more respiratory symptoms of influenza-like illness which may include the following:
    • Sore throat
    • Runny or stuffy nose
    • Cough
    • One or more constitutional symptoms of influenza-like illness which may include the following:
    • Myalgia (aches and pains)
    • Headache
    • Fatigue
  3. Subjects (or parent/guardian) willing and able to provide informed consent;
  4. Subjects must be enrolled in Arm 3 of the FLU-05 clinical study.

Written subject informed consent for this study protocol must be obtained prior to study enrollment. Each subject (or parent or guardian) must personally sign and date the Subject Informed Consent Form prior to his/her participation in this clinical study.

Exclusion Criteria:

  1. Subjects not presenting with at least three symptoms of influenza-like illness as outlined above.
  2. Subjects who have received influenza antiviral medication or an investigational influenza drug treatment within the previous 30 days of study enrollment.
  3. Subjects (children and adults) for whom the obtaining of aspirate samples is contraindicated or not possible.
  4. Subjects with a medical condition that prevents nasal washes or aspirate samples from being obtained.
  5. Active duty military personnel (participating military study sites only).
  6. Subjects (or parent/guardian) unwilling or unable to provide informed consent.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00828100
FLU-13
No
Philip Estes / Associate Director, Clinical, Nanogen, Inc.
Nanogen, Inc.
Not Provided
Not Provided
Nanogen, Inc.
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP